MedTrace Logo

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

NCT03778229 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 367

Last updated 2026-04-23

Study results available
· View outcomes & findings →

Summary

This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib

Conditions

  • Carcinoma

Interventions

DRUG

osimertinib

osimertinib (80 mg oral OD).

DRUG

savolitinib

savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)

DRUG

placebo

placebo to osimertinib (oral OD)

Sponsors & Collaborators

  • Hutchison Medipharma Limited

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Lecia V Sequist, MD MPH · Massachusetts General Hospital

  • Myung-Ju Ahn, MD · Samsung Medical Centre Sungkyunkwan University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-09
Primary Completion
2024-08-23
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • Canada
  • Chile
  • Denmark
  • France
  • India
  • Italy
  • Japan
  • South Korea
  • Spain
  • Taiwan
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03778229 on ClinicalTrials.gov